Best Treatment Choice for Osteonecrosis of the Jaw
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
BETCON is a pragmatic randomized controlled open-label multi-center study in patients with
newly diagnosed stage I-II MRONJ designed to answer the question whether minimally invasive
management with LPRF membranes or primary surgical treatment is better than the standard of
care of conservative therapy alone. The primary end-point is the time to mucosal healing.
Secondary end-points consist of supporting measures of efficacy, patient reported symptoms,
quality of life, well-being, and functioning.
Phase:
Phase 4
Details
Lead Sponsor:
Tim Van den Wyngaert
Collaborators:
Kom Op Tegen Kanker Kom op tegen Kanker (Stand up to Cancer)